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Pulmonary arterial hypertension (PAH) includes various forms of pulmonary hypertension of
different etiology but similar clinical presentation and functional derangement. Histopatho-
logical vascular changes in all forms of PAH are qualitatively similar but with quantitative
differences in the distribution and prevalence of pathological changes in various portions of
the pulmonary vascular bed. The documentation of these topographic variations in the
response of the pulmonary vasculature to injury may be important to understand the
pathogenesis of the various subsets of PAH. To standardize the precise histopathological
documentation of the pulmonary vasculopathy in PAH we propose a histopathological
classification that includes both the predominant segment of the pulmonary vasculature
affected and the possible coexistence of pathological changes in other vascular
segments. (J Am Coll Cardiol 2004;43:25S–32S) © 2004 by the American College of
Cardiology Foundationa
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fhe term pulmonary arterial hypertension (PAH) includes a
ariety of pulmonary hypertensive diseases with different eti-
logies but similar clinical presentation and, in many cases,
imilar response to medical treatment (1). Initially, PAH
omprised primary pulmonary hypertension (PPH) and pul-
onary hypertension related to left-to-right shunts, collagen-
ascular diseases, portal hypertension, human immunodefi-
iency virus (HIV) infection, ingestion of drugs or dietary
roducts, and persistent fetal circulation (1). At the recent
hird World Symposium on Pulmonary Artery Hypertension,
ulmonary veno-occlusive disease (PVOD) and pulmonary
apillary hemangiomatosis (PCH) have been incorporated into
AH because of the high incidence of arteriopathy in these
onditions (2,3), the similarity of risk factors with PAH (HIV,
rug ingestion), the familial occurrence (4,5), and the recently
iscovered mutation of bone morphometric protein receptor-2
BMPR2) in a case of PVOD (6). It has been hypothesized
hat PAH, PVOD, and PCH may represent part of the
pectrum of the same disease, or differing reactions to similar
nsults.
The Evian classification (1) is based on etiology, clinical
resentation, and functional data, and it assumes that all
ubsets of PAH have a similar spectrum of pathological lesions.
his may not always be the case because morphometric studies
ave shown differences in the distribution and prevalence of
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apworth Everard, Cambridge, United Kingdom; §Department of Pathology,
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opkins University, School of Medicine, Baltimore, Maryland.CManuscript received November 26, 2003; accepted February 3, 2004.rterial changes among PAH of different etiology (7,8). Also,
n certain cases of PAH venous changes coexist with arterial
esions; that is, the pulmonary veins and venules can show
ntimal and adventitial thickening and even arterialization
9–12). In the proximity of organized pulmonary infarcts,
eno-occlusive changes can also be present, possibly due to
carring or other disruptions of vascular relationships.
Thus, documentation of the extent of different types of
ascular changes among the various subsets of PAH is
ssential in understanding how various segments of the
ulmonary vascular tree react to injury. To standardize
athological reporting and provide clinicians with a precise
escription of the nature and extent of vascular lesions
resent in a single case, we have adopted a descriptive
istopathologic system of classification (Table 1) in which
oth the predominant changes and the coexisting patho-
ogic changes are recorded.
ANDLING OF LUNG TISSUE
ixation of the lung samples in a state of distension avoids
renation of elastic laminae of muscular pulmonary arteries
hat may induce a state of spurious medial hypertrophy.
dequate sampling of the lungs (at least five blocks from
ach lobe) is essential. The histological examination should
ndicate whether adequate samples of blood vessels are
resent, the nature and number of diseased blood vessels,
he presence, location, and nature of inflammatory cells, as
ell as any evidence of associated pathology in the airways
r lung parenchyma. In addition to hematoxylin-eosin
HE), special histological stains (Movat, Masson, Verhoeff-
an Gieson, Perls’ iron) are essential to assess vascular
athology. Also useful are immunohistochemical markers
or smooth muscle and endothelium (Factor VIII, CD31,
D 34).
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Histopathology of Pulmonary Hypertension June 16, 2004:25S–32SULMONARY ARTERIOPATHY
ll forms of pulmonary hypertension have some common
athologic features regardless of their etiology, that is,
edial hypertrophy of muscular and elastic arteries, dilation
nd intimal atheromas of elastic pulmonary arteries and
ight ventricular hypertrophy. These forms of pulmonary
ascular remodeling have limited diagnostic value because
hey are present in all forms of severity of pulmonary
able 1. Pathological Classification of Vasculopathies of Pulmona
. Pulmonary arteriopathy (pre- and intra-acinar arteries)
Subsets
Pulmonary arteriopathy with isolated medial hypertrophy
Pulmonary arteriopathy with medial hypertrophy and intimal thicken
Concentric laminar
Eccentric, concentric nonlaminar
Pulmonary arteriopathy with plexiform and/or dilation lesions or arte
Pulmonary arteriopathy with isolated arteritis
a. As above but with coexisting venous-venular changes (cellular and/or
thickening, muscularization)
The presence of the following changes should be noted:
Adventitial thickening; thrombotic lesions (fresh, organized, recanali
necrotizing or lympho-monocytic arteritis; elastic artery changes (fibr
intimal plaques, elastic laminae degeneration); bronchial vessel chang
incrustation, calcifications, foreign body emboli, organized infarct pe
infiltrates.
. Pulmonary occlusive venopathy (veins of various size and venules) with
coexisting arteriopathy
Histopathologic features:
Venous changes: intimal thickening/obstruction (cellular, fibrotic); ob
luminal septa (recanalization).
Adventitial thickening (fibrotic); muscularization; iron and calcium in
foreign body reaction:
Capillary changes: dilated, congested capillaries; angioma-like lesions
Interstitial changes: edema; fibrosis; hemosiderosis; lymphocytic infilt
Others: dilated lymphatics; alveoli with hemosiderin-laden macropha
hyperplasia.
. Pulmonary microvasculopathy with or without coexisting arteriopathy a
Histopathologic features:
Microvessel changes: localized capillary proliferations within pulmon
obstructive capillary proliferation in veins and venular walls.
Venous-venular intimal fibrosis.
Interstitial changes: edema, fibrosis, hemosiderosis.
Others: dilated lymphatics; alveoli with hemosiderin-laden macropha
hyperplasia.
. Unclassifiable‡
Nonvascular lung pathology needs to be listed as separate diagnosis. †Primary pulmo
nd T. Strasser, eds. ‡Atypical histopathological features or inadequate sampling of
Abbreviations and Acronyms
BMPR2  Bone morphometric protein receptor-2
HIV  human immunodeficiency virus
PAH  pulmonary arterial hypertension
PCH  pulmonary capillary hemangiomatosis
PM  pulmonary microvasculopathy
POV  pulmonary occlusive venopathy
PPH  primary pulmonary hypertension
PVOD  pulmonary veno-occlusive diseaseGr.  grade; n.a.  not applicable.ypertension. Also, pulmonary artery medial and intimal
hickening can occur as an isolated nonspecific finding in
ocalized areas of the lung or secondary to airway or
nterstitial diseases and tumors, with no direct relationship
o the presence or not of pulmonary hypertension.
In addition to the aforementioned pathologic changes
ommon to all forms of pulmonary hypertension, PAH is
haracterized by constrictive and complex arterial lesions
nvolving to varying degrees the pre- and intra-acinar
ulmonary arteries (3,12). The main histopathological fea-
ures of this pulmonary arteriopathy are illustrated in Figure
and are briefly defined below.
onstrictive lesions. These lesions include medial hyper-
rophy, and intimal and adventitial thickening. These
hanges are believed to result from an imbalance between
roliferation and apoptosis of the various cell types forming
he vascular walls. Because they are diffuse lesions, they may
e hemodynamically important if vasorelaxant properties are
ost (i.e., prostacyclin or nitric oxide) or there is excessive
ypertension*
Previous WHO terminology†
Pulmonary plexogenic arteriopathy Gr. 1
cellular, fibrotic)
Pulmonary plexogenic arteriopathy Gr. 2, 3
Pulmonary embolic arteriopathy
Pulmonary plexogenic arteriopathy Gr. 4–6
n.a.
ic intimal n.a.
olander lesion);
r atheromatous
rruginous
lar lymphocytic
ithout PVOD
tive fibrous
ation with
ype II cell
venopathy PCH
terstitium;
ype II cell
n.a.
ypertension. Report on a WHO meeting. Geneva, October 15–17, 1975. S. Hatano
vessels.ry H
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June 16, 2004:25S–32S Histopathology of Pulmonary Hypertensionroduction of vasoconstrictors (i.e., endothelin). Medial
ypertrophy is an increase in the cross-sectional area of the
edia of pre- and intra-acinar pulmonary arteries (Figs. 1A
nd 1B). It is due to both hypertrophy and hyperplasia of
mooth muscle fibers and to an increase in connective tissue
atrix and elastic fibers in the media of muscular arteries
nd extension of smooth muscle into nonmuscularized
ntra-acinar arteries. Medial hypertrophy entails both nu-
erical and phenotypical changes of muscle fibers. Atrophy
f the media occurs in arteries with marked intimal thick-
ning and in developing dilation lesions.
Intimal thickening can be of three types: concentric
aminar, eccentric, or concentric nonlaminar (Figs. 1C to
F). Concentric laminar intimal thickening can be to
arying degrees either cellular or fibrous (Figs. 1C and 1D).
oth ultrastructurally and immunohistochemically, the in-
imal cells show features of fibroblasts, myofibroblasts, and
mooth muscle cells (Fig. 1D). However, these morphologic
eatures do not allow conclusions on their derivation because
ecent experimental work has shown the potential of endo-
helial cells and fibroblasts to acquire smooth muscle phe-
otype (13). Concentric laminar intimal thickening is a
haracteristic feature of the so-called pulmonary plexogenic
rteriopathy and/or of scleroderma arteriopathy. Eccentric
nd concentric nonlaminar intimal thickenings are predom-
nantly composed of fibroblasts and connective tissue matrix
Figs. 1E and 1F). The notion that these changes are
iagnostic of thromboembolic arteriopathy needs revision
ecause intimal thickening may result from localized pro-
iferation of intimal fibroblasts caused by growth factors
eleased by hemodynamic stresses.
Adventitial thickening is difficult to evaluate because of its
ll-defined boundaries in conventional histological sections.
n most cases of PAH, the adventitia appears uninvolved,
ut it is expanded in pulmonary hypertension owing to
ersistent fetal circulation of the newborn.
OMPLEX LESIONS
lexiform lesions, dilation lesions, and arteritis are classified
s complex lesions. They are focal changes important as
arkers of either the severity or rapid progression of
ulmonary hypertension. It has also been suggested that
ndothelial proliferation in plexiform lesions of PPH may
e a marker of a fundamental cellular abnormality, possibly
f neoplastic nature (14,15).
The plexiform lesion is a focal proliferation of endothelial
hannels lined by myofibroblasts, smooth muscle cells, and
onnective tissue matrix. The lesion is located within pre-
nd intra-acinar pulmonary arteries and is associated with
xpansion and partial destruction of the arterial wall with
xtension of the plexiform lesion into the perivascular
onnective tissue (Figs. 1G and 1H). Within the plexiform
esion, fibrin thrombi and platelets are frequently present.
he plexiform lesion is often located at an arterial branching
oint, or at the origin of a supernumerary artery, distally to oarked obliterative intimal thickening of the parent artery.
he frequency of the plexiform lesion in PAH remains
ndetermined and probably varies to a great extent. Based
n studies with limited sampling, it is estimated that the
lexiform lesion involves from 20% to 60% of the pulmo-
ary arteries. It is extremely rare in PAH related to
onnective tissue diseases and it does not occur in PAH of
ersistent fetal circulation.
The localization of plexiform lesions along the arterial
ree also varies; that is, in congenital left-to-right shunts
hey tend to occur in arteries 100 to 200 m in external
iameter, whereas in PPH they tend to occur in arteries
100 m (3,12). Plexiform lesions may be difficult to
istinguish from the colander-like lesion of recanalized
hromboemboli (Fig. 1J). They are no longer considered
athognomonic for PPH as they have been found in PAH
ssociated with other diseases and even in chronic throm-
oembolic pulmonary hypertension (16). Endothelial cells
ithin plexiform lesions express vascular endothelium
rowth factor (VEGF) and its receptors (17), and the
esions are believed to result from disordered angiogenesis
ttributable to autonomous monoclonal endothelial prolif-
ration in the case of PPH (14,15). Recently, the association
f the vasculotropic human herpesvirus-8 with plexiform
esions of PPH has been demonstrated (18).
The dilation lesion is a thin-walled vein-like vessel (Figs.
H and 1I) usually located distally to a plexiform lesion.
his lesion may be the source of pulmonary hemorrhages
nd subsequent organization and fibrosis.
Arteritis is rarely primary in PAH; most often it is
ssociated with other complex lesions. The arterial wall may
e necrotic with fibrinoid insudation and/or be infiltrated
ith chronic and acute inflammatory cells (Fig. 1K).
In our histopathological classification, the terms “pulmo-
ary occlusive venopathy” (POV) and “pulmonary micro-
asculopathy” (PM) replace the old terms of PVOD and
CH, respectively (Table 1).
Pulmonary occlusive venopathy (POV) (formerly PVOD)
ccounts for a relatively small proportion of cases of pulmo-
ary hypertension. The diagnosis of POV and PM (de-
cribed below) in vivo is difficult and is not considered in
ost patients until signs of marked pulmonary hypertension
ave developed. Although, by high resolution computed
omography, patchy centrilobular ground-glass opacities,
hickened septal lines, pleural effusion, and mediastinal
denopathy are characteristic for POV and PM (19), the
ornerstone of the diagnosis of POV/PM is histopathology.
he main pathology of POV consists of extensive and
iffuse occlusion of pulmonary venules and veins of various
izes (2,5). The occluding fibrous tissue may be loose and
dematous with variable cellularity, or dense, sclerotic, and
cellular (Fig. 2A). The intimal thickening of POV involves
enules and small veins and rarely extends to the larger
eins. The luminal occlusion can be either solid or eccentric
ith multiple lumina (Fig. 2B), suggestive of recanalization
f occlusive thrombi. The media of the venules and veins
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Histopathology of Pulmonary Hypertension June 16, 2004:25S–32Say become thickened with an increase in elastic fibers and
mooth muscle (i.e., so-called arterialization). All these
orphological features are helpful in distinguishing POV
rom chronic venous hypertension.
A nonspecific but useful histological feature is the pres-
nce of calcium-encrusting elastic fibers in the walls of veins
igure 1. Main histopathological features of pulmonary arteriopathy (see te
nless specified.) Medial hypertrophy: (A) preacinar pulmonary artery, 
ntra-acinar artery,500; (D) pre-acinar artery. The vessel was decorated w
white arrow) to be composed of SMA-positive cells, 150. Eccentric (E
rteries. Plexiform lesions: (G) intra-acinar artery decorated with SMA
MA-positive cells (rusty color), 380; (H) pre-acinar artery adjacent to
ilation lesions (arrows), 40; (J) colander-like lesion, HE 400; (K) lyr adjacent alveoli. This feature, when present, renders the eeins easily identifiable and is therefore a pertinent histo-
ogical finding when the diagnosis of PVOD (or, indeed,
ulmonary hypertension) has not been raised by the refer-
ing clinician. Another feature that is useful in distinguish-
ng between POV and chronic passive venous hypertension
s the foreign body giant-cell response to the calcium-
details). (All histological sections were stained with Verhoeff-van Gieson
) intra-acinar artery, 600. Concentric laminar intimal thickening: (C)
ti-smooth muscle actin antibodies (SMA), revealing the intimal thickening
00 and concentric nonlaminar (F) 100 intimal thickening of pre-acinar
wing SMA-negative endothelial cells (arrow) surrounded by a rim of
exiform lesion (arrow) and dilation lesions (shown by asterisk) 60. (I)
monocytic arteritis, HE, 300.xt for
80; (B
ith an
) 1
sho
a pl
mphoncrusted elastic fibers. This feature is also helpful when
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June 16, 2004:25S–32S Histopathology of Pulmonary HypertensionOV is being considered as a supplementary diagnosis to
nother pulmonary pathology (i.e., interstitial lung disease
r emphysema), a circumstance not uncommon in lung
xplant pathology.
In POV, large amounts of hemosiderin are found both
ithin the cytoplasm of alveolar macrophages and type II
neumocytes as well as deposits in the interstitium. The
resence of fresh blood and/or hemosiderin may be so
rominent that idiopathic hemosiderosis or healed Wege-
er’s granulomatosis or other vasculitis is suggested. Hemo-
iderosis can be quite striking, and quantification of occult
lveolar hemorrhage in bronchoalveolar lavage (BAL)
19,20) has been successfully used to confirm the clinical
iagnosis of POV/PM because BAL hemorrhage is not a
sual feature of the other forms of PAH. The capillary
essels are engorged and prominent; they may become so
ortuous as to resemble pulmonary capillary hemangioma-
osis (21,22). The capillaries are generally easily identifiable
ithin the alveolar septa and do not line both sides of the
lveolar walls as seen in PM (PCH).
igure 2. Pulmonary occlusive venopathy. (A) Septal veins with nearly occlu
arrow), and congested alveolar capillaries. Verhoeff-van Gieson staining,
septal vein, 200. Pulmonary microvasculopathy. (C) Focal thickening
roliferation, hemosiderin-laden alveolar macrophages and type II pneumPulmonary arteries and arterioles can show remodeling inpproximately 50% of POV cases with moderate to severe
edial hypertrophy and arterialization. Plexiform lesions
nd fibrinoid arteritis are not described in POV (2). The
ulmonary interstitium shows edema particularly located in
he lobular septa, which may progress to interstitial fibrosis.
his can be sufficiently extensive to raise the possibility of
nterstitial lung disease such as usual interstitial pneumoni-
is. Inflammatory lung disease is further mimicked by the
arked lymphocytic interstitial infiltrate that is seen in
ome cases of POV. Lymphatics within the lung and pleura
re dilated in POV (Fig. 2A).
Pulmonary microvasculopathy (formerly PCH) is another
are condition characterized by localized capillary prolifer-
tion within the lung in which capillaries invade pulmonary
nterstitium, vessels, and, less commonly, airways (23). The
istribution of PM in the lungs is usually panlobar and
atchy, resembling an interstitial process at low magnifica-
ion and mimicking pulmonary congestion (24). However,
loser inspection shows diffuse proliferation of microvessels
ontaining large numbers of erythrocytes (Figs. 2C and 2D).
hese microvessels can form glomeroloid tufts or nodules
mens by fibrous intimal thickening (asterisk), marked lymphatic dilation
(B) Obstructive fibrous intimal thickening and recanalization channels in
veolar septa by proliferated capillaries, HE,20. (D) Nodular capillary
(arrows), HE, 300.ded lu
50.
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Histopathology of Pulmonary Hypertension June 16, 2004:25S–32Shat may project into the lumen of veins and lymphatics and
ithin air spaces. A distinguishing feature, which is best
ppreciated on reticulin staining, is the presence of mi-
rovessels on both sides of the alveolar walls. Havlik et al.
25) require the microvessels to form at least two cell layers
ithin the proliferating lesion for diagnosis. The endothelial
ells of the abnormal capillaries are cytologically bland with
longated oval nuclei, diffuse chromatin, and indistinct
ytoplasm. Mitoses are not frequently seen despite the
pparent proliferative nature of the condition. The abnor-
al proliferating capillaries extend into bronchovascular
undles; they infiltrate the walls of arterioles, arteries,
enules, and veins, invading muscular walls and occluding
he lumens. Also, microvascular proliferation has been seen
n perineural and intraneural positions, in the pleura, and in
ymph nodes. Venous occlusion by proliferating capillaries
nd related intimal fibrosis is distinct from the nonangio-
enic occlusion of veins in POV.
In the areas of capillary proliferation, a striking feature is
ulmonary hemosiderosis represented by both fresh hemor-
hage and abundant hemosiderin-laden macrophages and
ype II pneumocytes (Fig. 2D). However, cases without
triking hemosiderosis are observed. The infiltrating capil-
aries can mimic plexiform lesions, but neither these nor
ilation lesions have been described in PM. Similar to POV,
he pulmonary arteries in PM show marked muscular
ypertrophy and intimal thickening, but, unlike POV,
esions resembling thrombosis are not a feature.
The pathogenesis of PM (PCH) is controversial. Some
nvestigators consider PM to be neoplastic (26), and it is
nteresting that some patients with PM have responded to
reatment with interferon-, which presumably acts by
epressing endothelial proliferation (27,28). Conversely,
M may be due to unknown angiogenic stimuli, and the
nfiltrative aspect of the disease may merely be related to the
xtension of vascular lesions within a preexisting vascular
istribution.
The PCH/PM-like lesions, as described by Havlik et al.
25), are not associated with clinical pulmonary hyperten-
ion and do not generally show invasion of small vessels with
cclusion. Pulmonary microvasculopathy and PCH/PM-
ike lesions must be carefully distinguished from severe
ulmonary congestion and atelectasis (29).
Previously PM was described as a possible hypertensive
asculopathy, such lesions had been described as prominent,
yperplastic capillaries with pseudoangiomatous features.
ncreasing familiarity with the entity of PM has drawn
ttention to overlaps and similarities between this and POV,
articularly in relation to the parenchymal changes of
emosiderosis, fibrosis, lymphatic dilation and edema, and
he similar arterial modifications of intimal fibrosis and
edial hypertrophy. The distinction between the two enti-
ies is clear in those cases where the venous obliteration in
M is due to proliferating capillaries and in POV due to
ntimal fibrosis with or without recanalization.
Some cases are, however, less clear-cut, and the issue is eurther confounded by the description of PCH/PM-like
esions that can occur in several clinicopathological settings
nd that have even been described at autopsy in the absence
f evidence of pulmonary hypertension. Clearly, use of the
erm “PCH/PM-like lesions” must be strict and contextual
f confusion is to be avoided. This is an area where there is
likely future role for molecular pathology in distinguishing
ilation and tortuosity of existing capillaries from capillary
ngiogenesis and in elucidating the relationship to vascular
emodeling and growth factors. It is important to note that
imilar microvasculopathy is usual in severe mitral valve
isease, and interpretation of venous and capillary conges-
ion with or without proliferation should be made in the
nowledge of any valvular disease.
As with many pathological conditions that are poorly
nderstood, it is tempting to consider lesions as part of a
ontinual spectrum, and this view has been justified in
elation to POV, POV with PM-like lesions, and true PM,
ccording to whether the venous or capillary lesions are
elieved to predominate. This can be a hazardous approach
f the nature of the sample is not specified. It is likely that
xplant or autopsy examination of an entire lung will
roduce a different emphasis on a putative spectrum than
ill analysis of biopsy material. One point that is abundantly
lear, however, is the critical importance of recognizing both
OV and PM as rare causes of unexplained pulmonary
ypertension because the treatment with vasoactive agents is
ontraindicated and may even be life-threatening (30,31).
resently, the final distinction between POV and PM
equires tissue diagnosis, which is not always feasible. Both
he role and the need for lung biopsy in the diagnosis and
anagement of pulmonary hypertension are still under
ebate.
Pulmonary occlusive venopathy and PM are rather un-
ommon (fewer than 200 cases have been reported in the
ublished data) but increasingly recognized causes of pul-
onary hypertension. They could represent part of the
pectrum of vasculopathies of PPH, but they are distinct
rom the precapillary causes of PAH. The hypertensive
ngiopathies with exclusive involvement of the precapillary
ed share similar morphological lesions of intimal fibrosis,
edial hypertrophy, and plexiform lesions, and they gener-
lly have a favorable response to drugs such as epoprostenol.
atients with POV and PM may respond to vasodilators
ith life-threatening edema, and it is therefore of great
linical importance that they be distinguished from precap-
llary PAH (30,31). It is well recognized that POV in some
ases shows extensive abnormality of the pulmonary arterial
ascular bed with apparently equal involvement of the
enous and arterial components of the circulation. For this
ituation, the term “pulmonary vascular occlusive disease”
as been adopted, but in the current state of pathogenetic
nowledge it may itself be confusing (32).
In relation to the second issue, the term pulmonary
ascular occlusive disease (or vaso-occlusive) generally denotes
xtensive involvement of large and small pulmonary arteries
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June 16, 2004:25S–32S Histopathology of Pulmonary Hypertensiony narrowing or occlusion of the same type of intimal fibrosis
s seen in the pulmonary veins, indicating that the tendency
o thrombosis was not limited to the veins but also affected
he arteries. The availability of explant or autopsy tissue may
efine the main focus of the vascular pathology on either the
enous or arterial aspects of the pulmonary circulation (as
ompared to biopsy material), but there is no doubt that,
ven with whole lungs to examine, some cases are difficult to
lassify. Significant advances in the genetics and pathogen-
sis of pulmonary hypertension may help to resolve these
ssues.
Additionally, it is now well described that abnormalities in
one morphometric protein receptor-2 (BMPR2) signaling
lays a significant role in the majority of familial and in some
poradic cases of pulmonary hypertension. It is therefore
ascinating to note a case (6) of POV (PVOD) apparently
aused by an inherited mutation in BMPR2. There was no
istopathological assessment of the proband mother’s pulmo-
ary hypertension, but features characteristic of POV were
ound in the proband herself (6) upon review of the open-lung
iopsy. Interestingly, the patient improved clinically with
poprostenol and has remained stable for many years, which is
uite uncommon in POV. It is likely that the systematic and
niform description of the nature and extent of widespread
rterial lesions in PVO/PM and the coexistence of venous
esions in PAH, as recommended in the new pathological
lassification, together with studies of BMPR2, BMPR1a,
IE-2, and angiopoietin expression in the various forms of
ulmonary vasculopathy, will provide information about
he position of predominantly arterial, venous, capillary,
r mixed forms on a clinical and histological spectrum
33). These exciting developments will surely enable a
etter informed analysis of the links between POV and
CH/PM with precapillary pulmonary hypertension.
his may also allow further refinement of PCH-like
esions in these settings and also in chronic pulmonary
enous hypertension. Similar studies may shed light on
apillary angiogenesis versus congestion and dilation.
rimary pulmonary hypertension appears now to be an
ngioproliferative disease, and PCH/PM may represent
ncontrolled angiogenesis, either de novo or arising from
reactive/hyperplastic process.
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